{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(9)"],"submitter":["Pascual T"],"funding":["Pfizer"],"pubmed_abstract":["<h4>Background</h4>The SOLTI-1303-PATRICIA trial (NCT02448420) is a phase II study investigating palbociclib and trastuzumab, with or without endocrine therapy, in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). This manuscript presents final overall survival (OS) results and biomarker analyses.<h4>Patients and methods</h4>Patients previously treated with trastuzumab and two to four regimens were eligible. For estrogen receptor (ER)-negative disease (cohort A), patients received palbociclib and trastuzumab. For ER-positive disease, patients were randomized 1 : 1 to cohort B1 (no additional therapy) or B2 (letrozole). OS and long-term progression-free survival (PFS) were pre-defined secondary endpoints. Kaplan-Meier cur"],"journal":["ESMO open"],"pagination":["105572"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12424417"],"repository":["biostudies-literature"],"pubmed_title":["Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial."],"pmcid":["PMC12424417"],"pubmed_authors":["Pernas S","Adamo B","Prat A","Villanueva L","Gonzalez-Rodriguez M","Galvan P","Gonzalez-Farre X","Ferrero-Cafiero JM","Nuciforo P","Galan M","Canes J","Tolosa P","Ciruelos E","Gonzalez-Farre B","Villacampa G","Oliveira M","Perello A","Villagrasa P","Mele M","Cortes J","Pascual T","Escriva-de-Romani S","Martinez E","Pare L"],"additional_accession":[]},"is_claimable":false,"name":"Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial.","description":"<h4>Background</h4>The SOLTI-1303-PATRICIA trial (NCT02448420) is a phase II study investigating palbociclib and trastuzumab, with or without endocrine therapy, in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). This manuscript presents final overall survival (OS) results and biomarker analyses.<h4>Patients and methods</h4>Patients previously treated with trastuzumab and two to four regimens were eligible. For estrogen receptor (ER)-negative disease (cohort A), patients received palbociclib and trastuzumab. For ER-positive disease, patients were randomized 1 : 1 to cohort B1 (no additional therapy) or B2 (letrozole). OS and long-term progression-free survival (PFS) were pre-defined secondary endpoints. Kaplan-Meier cur","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-03T07:44:16.161Z","creation":"2026-04-26T03:09:47.076Z"},"accession":"S-EPMC12424417","cross_references":{"pubmed":["40896880"],"doi":["10.1016/j.esmoop.2025.105572"]}}